Schizophrenia, Paranoid  >>  MK0249  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK0249 / Merck (MSD)
NCT00506077: MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

Completed
2a
55
RoW
MK0249, Comparator: Placebo (unspecified)
Merck Sharp & Dohme LLC
Paranoid Schizophrenia
10/08
10/08

Download Options